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Role of glucose-6-phosphate dehydrogenase inhibition in
the antiproliferative effects of dehydroepiandrosterone
on human breast cancer cells
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Summary Epidemiological and experimental studies suggest that dehydroepiandrosterone (DHEA) exerts a protective effect against breast
cancer. It has been proposed that the non-competitive inhibition of glucose-6-phosphate dehydrogenase (G6PD) contributes to DHEA anti-
tumour action. We evaluated the effects of DHEA on G6PD activity and on the in vitro proliferation of two human breast cancer cell lines,
MCF-7 (steroid receptor positive) and MDA-MB-231 (steroid receptor negative), in a serum-free assay. DHEA inhibition of G6PD was only
found to occur at concentrations above 10 gm; at these high concentrations, the growth curve was parallel to the enzyme inhibition curve in
both cell lines. In contrast, at concentrations in the in vivo breast tissue concentration range, neither cell growth nor enzyme activity was
inhibited. The results failed to confirm DHEA's putative anti-tumour action on breast cancer through G6PD inhibition, as the enzyme blockade
only becomes apparent at pharmacological concentrations of the steroid.
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INTRODUCTION
Epidemiological studies in premenopausal women show that
plasma and urine levels of dehydroepiandrosterone (DHEA) and
its sulphated metabolite (DHEAS) are inversely related to breast
cancer risk, suggesting a protective effect of DHEA against breast
cancer (Bulbrook et al, 1962, 1971; Brownsey et al, 1972; Wang et
al, 1974, Rose et al, 1977; Zumoff et al, 1981). Moreover, DHEA
administration in rodents blocks the development of both sponta-
neous and carcinogen-induced tumours of various organs,
including the mammary gland (Schwartz, 1979; Schwartz and
Tannen, 1981; Schwartz et al, 1981, 1986; Pashko et al., 1984,
1985; Moore et al, 1986a,b; Boccuzzi et al, 1992a). DHEA effect
on breast cancer growth may depend on its hormonal activity via
steroid receptors (SR), as DHEA is metabolized in breast tissue to
5-en-androstene-3 P, 17 ,-diol (ADIOL), a compound with both
oestrogenic and androgenic properties (Poortman et al, 1975;
Hackenberg et al, 1993). However, the prevailing hormonal
activity of DHEA is to stimulate cell growth via the oestrogen
receptors (ERs) (Adams et al, 1981; Najid and Habrioux, 1990;
Pizzini et al, 1992), whereas its antiproliferative effect, due to
androgen receptor (AR) binding (Hackemberg et al, 1993),
becomes appreciable only when ERs are blocked (Boccuzzi et al,
1993, 1994). Besides the SR-mediated effects, DHEA has been
shown to exert numerous activities in both physiological and
pathological conditions via 'non-hormonal' mechanism(s)
(Ebeling and Koivisto, 1994). The inhibition of glucose-6-phos-
phate dehydrogenase (G6PD) activity by DHEA has been claimed
to play a major role in preventing carcinogenesis, as well as
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exerting an anti-obesity action in rats (Schwartz et al, 1988; Cleary
1991; Schwartz and Pashko, 1993). The inhibition of the G6PD
pathway (Benes and Oertel, 1971; Feo et al, 1987) might explain
the protective action of DHEA against breast cancer (Schwartz et
al, 1988). In agreement with this hypothesis, it has been reported
that breast cancer risk is reduced in G6PD-deficient women (Feo
et al, 1984, 1987). To differentiate between SR-dependent and SR-
independent actions of DHEA on breast cancer cell growth, we
used a serum-free assay to evaluate G6PD activity in MDA-MB-
231 (hormone unresponsive) and in MCF-7 (hormone-responsive)
breast cancer cell lines cultured in the presence ofDHEA.
MATERIALS AND METHODS
Dehydroepiandrosterone (DHEA) (Sigma Chemicals, USA) was
diluted in ethanol; the final concentration ofethanol in the medium
did not exceed 0.1% and had no detectable effect on cell growth.
Nevertheless, the same concentration of ethanol was added to the
control culture medium.
Fetal calf serum (FCS) (Eurobio, France) was extracted with
charcoal dextran (10:1), to remove steroids, at 25°C for 60 min.
The serum-free medium comprised: RPMI-1640 phenol red-free
medium (Sigma Chemicals) plus 2mM L-glutamine (Eurobio,
France), 100 IU ml penicillin G, 100 gg mll streptomycin, 2 mg
1-' human transferrin (Sigma Chemicals) and 20 mM Hepes
buffer (Sigma Chemicals). MCF-7 (oestrogen, progesterone and
androgen receptor positive) and MDA-MB-231 (oestrogen, prog-
esterone and androgen receptor negative) cell lines were from the
American Type Culture Collection (USA); cells were routinely
cultured in 25-cm2 plastic flasks (Falcon, USA) in RPMI-1640
phenol red-free medium plus 10% FCS. The cells were grown in a
humidified atmosphere containing 5% (v/v) carbon dioxide at
37°C. Weekly, the cells were passaged by 0.05% trypsin and
0.02% EDTA. Approximately 4 x 104 cells per well were plated in
triplicate on 24-well culture plates (Falcon, USA). Cells were
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Figure 1 Effects of DHEA on cell growth. Approximately 4 x 104 cells per
well were plated in triplicate in 24-well culture plates. Cells were allowed to
attach for 24 h in the medium supplemented with 10% steroid-stripped FCS.
The seeding medium was then replaced with a serum-free medium
containing DHEA (0.05-50 gM). Control cells were grown in steroid-free
medium. The medium was renewed on the 4th day. Cells in the exponential
growth phase were harvested seven days after plating and counted. Results
are expressed as percentage variation of cell numbers compared with the
control group (taken as 100%). Each point represents the mean + s.d. of
eight experiments performed in triplicate. A, MDA-MB-231; A, MCF-7
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Figure 2 Effects of DHEA on G6PD activity. Cells at confluence were
harvested, suspended in Tris 0.1 M (7.5 x 104 cells per 50 RI) and
homogenized. G6PD activity in the presence of DHEA is expressed as
percentage variation of enzyme activity compared with control cells (taken
as 100%). Each point represents the mean of five experiments. Standard
deviations (not shown) were below 12% in all cases. A, MDA-MB-231;
A, MCF-7
allowed to attach for 24 h in the medium supplemented with 10%
steroid-stripped FCS. The seeding medium was then replaced with
a serum-free medium containing DHEA (0.05-50 tM). Control
cells were grown in steroid-free medium. The medium was
renewed on the fourth day. Cells in the exponential growth phase
were harvested by trypsin 7 days after plating and counted (twice
for each well) in a Burker's chamber. G6PD activity was measured
using the Glock and McLean assay (Glock and McLean, 1953).
Equal numbers of cells for each condition were suspended in Tris
0.1 M (7.5 x 104 cells per 50 ,ul) and homogenized in bursts of
3-5 s in a Polytron PT1O, with 30 s cooling in ice between bursts.
The homogenates were centrifuged (4°C) at 70 000g for 60 min.
The lower layer (20 tl) was incubated at 37°C for 10 min with
930 ,ul of Tris 0.1 M buffer plus NADP (3.5 mg ml-') and magne-
sium chloride (0.5 M). At time zero, the reaction substrate was
added (50 ,tl of 3.38 mg ml-' glucose 6-phosphate and/or 50 tl of
4.75 mg ml-' 6-phosphogluconate). The amount of NADP reduc-
tion was calculated at 15-min intervals throughout a 3 h period as
variation ofabsorbance at 366 nm and at 37°C.
RESULTS
The effect of different concentrations of DHEA (0.05-50 gM) on
the growth of MCF-7 and MDA-MB-23 1 cells is shown in Figure
1. At low concentrations (in the range of those found in breast
tissue) (van Landeghem et al, 1985), DHEA only modified the
growth of hormone-responsive MCF-7 cells; on day 7 of culture,
growth of MCF-7 cells was stimulated, whereas no effect on the
proliferation of hormone-unresponsive MDA-MB-231 cells was
detectable. Conversely, at high concentrations (20-50 ,UM), the
effect of DHEA appeared not to be influenced by steroid receptor
availability; the effect exerted on cell growth of the two cell lines
was similar, growth inhibition of the same amplitude being
produced. G6PD activity was measured in cell homogenates in the
presence of increasing concentrations of DHEA (0.05-50 ,UM).
Enzyme activity in the two cell lines is shown in Figure 2; no inhi-
bition was detectable for DHEA concentrations up to 5 ,UM,
whereas a dose-dependent inhibition was observed at concentra-
tions above 10 ,UM. The effect on enzyme activity was similar in
the two cell lines.
DISCUSSION
Results show that DHEA, at concentrations considerably above
those found in vivo in breast tissue (van Landeghem et al, 1985),
inhibits both G6PD activity and cell growth. Previous research has
failed to demonstrate any inhibitory effect of DHEA on breast
cancer cell growth in vitro (Poulin and Labrie, 1986; Boccuzzi et
al, 1993). However, the putative inhibition of cell growth via
G6PD blockade may have not been evident because of the pres-
ence of serum in the culture medium; serum (fetal calf derived)
can mask the antiproliferative action ofG6PD inhibition (Dworkin
et al, 1986), probably because of its high nucleoside content (Feo
et al, 1991; Pashko et al, 1991). Moreover, the use of a hormone-
responsive cell line obscures the mechanism of the action on cell
growth because of the overlap of hormonal and non-hormonal
effects. More precisely, the proliferative effects of DHEA that are
due to ER binding of its metabolite ADIOL (Adams et al, 1981;
Najid and Habrioux, 1990) may mask an antiproliferative action
because of G6PD inhibition. In view ofthis, we evaluated DHEA
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action on G6PD activity and growth in both SR-negative and SR-
positive cells. Nucleoside interference was avoided by using a
serum-free assay. Data show that, as DHEA concentrations
increase, the growth curve parallels the enzyme inhibition curve.
This effect probably depends on the reduced availability of ribose
phosphate, resulting in reduced DNA synthesis (Dworkin et al,
1986; Feo et al, 1991; Pashko et al, 1991). However, the inhibitory
effect is appreciable only for DHEA concentrations well above
those found in vivo in breast tissue. At these high DHEA concen-
trations, SR expression does not influence the effect on the growth
of the two cell lines. While high DHEA concentrations exert an
effect on both growth and G6PD activity that is similar in the two
cell lines, the effect of DHEA at concentrations found in vivo in
breast tissue is conditioned by SR expression. Neither G6PD
activity nor cell growth is affected by DHEA in SR- cells;
conversely, the growth ofthe SR+ cells is stimulated by DHEA, but
G6PD activity is not affected. The stimulatory action of DHEA on
cell growth depends on its metabolization to ADIOL, a compound
which binds to ERs (Adams et al, 1981; Najid and Habrioux, 1990;
Boccuzzi et al, 1992b, Pizzini et al, 1992).
This result does not support the theory that DHEA plays a role
in the growth of breast cancer through G6PD modulation. The
reports that suggest that DHEA inhibition of G6PD explains
DHEA's protective effect against mammary cancer growth in
rodents comprised prolonged treatment with pharmacological
doses of the steroid (Schwartz et al, 1988; Schwartz and Pashko,
1993). Our in vitro model demonstrates that only the hormonal
properties of DHEA are appreciable when the steroid is tested at
concentrations found in breast tissue. The action on the enzyme
would appear to be pharmacological in nature.
REFERENCES
Adams J, Garcia M and Rochefort H (1981) Estrogenic effects ofphysiological
concentrations of5-en-androstene-31-17p-diol and its metabolism in MCF-7
human breast cancer cells. Cancer Res 41: 4720-4726
Benes P and Oertel G (1971 ) Steroid structure and inhibition ofglucose-6-phosphate
dehydrogenase. JSteroid Biochem 2: 289-292
Boccuzzi G, Aragno M, Brignardello E, Tamagno E, Conti G, Di Monaco M,
Racca S, Danni 0 and Di Carlo F (1992a) Opposite effects of
deydroepiandrosterone on the growth of7,12-dimethylbenz (A) anthracene-
induced rat mammary carcinomas. Anticancer Res 12: 1479-1484
Boccuzzi G, Brignardello E, Di Monaco M, Forte C, Leonardi L and Pizzini A
(1992b) Influence ofdehydroepiandrosterone and5-en-androstene-3p, 17f-diol
on the growth ofMCF-7 human breast cancer cells induced by 17f-estradiol.
Anticancer Res 12: 799-804
Boccuzzi G, Di Monaco M, Brignardello E, Leonardi L, Gatto V, Pizzini A and
Gallo M (1993) Dehydroepiandrosterone antiestrogenic action through
androgen receptor in MCF-7 human breast cancer cell line. Anticantcer Res 13:
2267-2272
Boccuzzi G, Brignardello E, Di Monaco M, Gatto V, Leonardi L, Pizzini A and
Gallo M (1994) 5-en-androstene-3p, 17p-diol inhibits the growth of MCF-7
breast cancer cells when estrogen receptors are blocked by estradiol. Br J
Cancer70: 1035-1039
Brownsey B, Cameron E, Griffiths K, Gleave E, Forrest A and Campbell H (1972)
Plasma dehydroepiandrosterone sulfate levels in patients with benign and
malignant breast disease. Eut J Cancer 8: 131-137
Bulbrook R, Hayward J, Spicer C and Thomas B (1962) Abnormal excretion of
urinary steroids by women with early breast cancer. Lancet 2: 1238-1240
Bulbrook R, Hayward J and Spicer C (1971 ) Relation between urinary androgen and
corticoid excretion and subsequent breast cancer Lancet 2: 395-398
Cleary M (1991) The antiobesity effect ofdehydroepiandrosterone in rats. Proc Soc
Exper Biol Med 196: 8-16
Dworkin C, Gorman S, Pashko L, Cristofalo V and Schwartz A (1986) Inhibition of
growth of HeLa and WI-38 cells by dehydroepiandrosterone and its reversal by
ribo- and deoxyribonucleosides. Life Sci 38: 1451-1457
Ebeling P and Koivisto V (1994) Physiological importance of
dehydroepiandrosterone. Lancet 343: 1479-1481
Feo F, Pirisi L, Pascale R, Daino L, Frassetto S, Garcea R and Gaspa L (1984)
Modulatory effect ofglucose-6-phosphate dehydrogenase deficiency on
benzo(a)pyrene toxicity and transforming activity for in vitro-cultured human
skin fibroblasts. Cancer Res 44: 3419-3425
Feo F, Garcea R, Daino L, Frassetto S, Cozzolino P, Ruggiu M, Vannini M,
Pascale R, Lenzerini L, Simile M and Puddu M (1987) Inhibition of
initiation and promotion steps ofcarcinogenesis by glucose-6-phosphate
dehydrogenase deficiency. In Chemical Carcinogenesis: Models and
Mechanisms, Feo F, Pani P, Columbano A and Garcea R (eds), pp. 369-375
Plenum Press: New York
Feo F, Daino L, Seddaiu M, Simile M, Pascale R, Mckeating J, Davliakos G, Sudol
K, Melhem M and Rao K (1991) Differential effects ofdehydroepiandrosterone
and deoxyribonucleosides on DNA synthesis and de novo cholesterogenesis in
hepatocarcinogenesis in rats. Carcinogenesis 12: 1581-1586
Glock GE and McLean P (1953) Further studies on the properties and assay of
glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase of
rat liver. Bioche,n J 55: 400-408
Hackenberg R, Turgetto I, Filmer A and Schulz K (1993) Estrogen and androgen
receptor mediated stimulation and inhibition ofproliferation by androst-5-ene-
3I, 17f-diol in human mammary cancer cells. J Steroid Biochem Mol Biol 46:
597-603
Moore M, Thamavit W, Tsuda H, Sato K, Icihara A and Ito N (1986a) Modifying
influence ofdehydroepiandrosterone on the development ofdihydroxy-di-n-
propylnitrosamine-initiated lesions in the thyroid, lung and liver of F344 rats.
Carcinogenesis 7: 311-316
Moore M, Thamavit W, Ichihara A, Sato K and Ito N (I986b) Influence of
dehydroepiandrosterone, diaminopropane and butylated hydroxyanisole
treatment during the induction phase of rat liver nodular lesions in short-term
systems. Carcinogenesis 7: 1059-1063
Najid A and Habrioux G (1990) Biological effects of adrenal androgens on MCF-7
and BT-20 human breast cancer cells. Oncology 47: 269-274
Pashko L, Rovito R, Williams J, Sobel E and Schwartz A (I1984)
Dehydroepiandrosterone (DHEA) and 3,-methylandrost-5-en-17-one:
inhibition of 7,12-dimethylbenz(a) anthracene (DMBA)-initiated and 12-0-
tetradecanoylphorbol- 13-acetate (TPA)-promoted skin papilloma formation in
mice. Carcinogenesis 5: 463-466
Pashko L, Hard G, Rovito R, Williams J, Sobel E and Schwartz A (1985) Inhibition
of7,12-dimethylbenz(a) anthracene-induced skin papillomas and carcinomas
by dehydroepiandrosterone and 3 ,-methylandrost-5-en-17-one in mice.
Cancer Res 45: 164-166
Pashko L, Lewbart M and Schwartz A (1991) Inhibition of 12-o-
tetradecanoylphorbol- 13-acetate-promoted skin tumor formation in mice by 16
alpha-fluoro-5-androsten- 17-one and its reversal by deoxyribonucleosides.
Carcinogenesis 12: 2189-2192
Pizzini A, Brignardello E, Leonardi L, Di Monaco M and Boccuzzi G (1992)
Aromatase fails to mediate the proliferative effects of adrenal androgens on
cultured MCF-7 breast cancer cells. Int J Oncol 1: 709-712
Poortman J, Prenen J, Schwarz F and Thijssen J (1975) Interaction of 5-en-
androstene-3p, 17,-diol with estradiol and dihydrotestosterone receptors in
human myometrial and mammary cancer tissue. J Clin Enidocrinol Metab 40:
373-379
Poulin R and Labrie F (1986) Stimulation ofcell proliferation and estrogenic
response by adrenal C19-A5 steroids in the ZR-75- 1 in human breast cancer cell
line. Cancer Res 46: 49334937
Rose D, Stauber P, Thiel A, Crowley J and Milbrath J (1977) Plasma
dehydroepiandrosterone sulfate, androstenedione and cortisol, and urinary free
cortisol excretion in breast cancer. EurJ Cancer 13: 4347
Schwartz A (1979). Inhibition of spontaneous breast cancer formation in female
C3H (A'Y/a) mice by long-term treatment with dehydroepiandrosterone. Cancer
Res 39: 1129-1132
Schwartz A and Tannen R (1981) Inhibition of7,12-dimethylbenz(a)anthracene- and
urethan-induced lung tumor formation in A/J mice by long-term treatment with
dehydroepiandrosterone. Carcinogenesis 2: 1335-1337
Schwartz A and Pashko L (1993) Cancer chemoprevention with the adrenocortical
steroid dehydroepiandrosterone and structural analogs. J Cell Bioche,n 17:
73-79
Schwartz A, Hard G, Pashko L, Abou-Gharbia M and Swem D (1981)
Dehydroepiandrosterone: an anti-obesity and anti-carcinogenic agent. Nutr
Cancer 3: 46-53
Schwartz A, Pashko L and Whitcomb J (1986) Inhibition of tumor development
by dehydroepiandrosterone and related steroids. Toxicol Path 14:
357-362
C Cancer Research Campaign 1997 British Journal ofCancer (1997) 75(4), 589-592592 M DiMonaco etal
Schwartz A, Whitcomb J, Nyce J, Lewbart M and Pashko L (1988)
Dehydroepiandrosterone and structural analogs: a new class ofcancer
chemopreventive agents. Adv Cancer Res 51: 391-424
Van Landeghem A, Poortman J, Nabuurs M and Thijssen J (1985)
Endogenous concentrations and subcellular distribution ofandrogens in
normal and malignant human breast tissue. Cancer Res 45:
2907-2912
Wang D, Bulbrook R, Herian M and Hayward J (1974). Studies on the sulfate esters
ofdehydroepiandrosterone and androsterone in the blood ofwomen with breast
cancer. EurJ Cancer 10: 477-482
ZumoffB, Levin J, Rosenfeld R, Markham M, Strain G and Fukushima D (1981)
Abnormal 24-hour mean plasma concentrations ofdehydroepiandrosterone
sulfate in women with primary operable breast cancer. CancerRes 41:
3360-3363
British Journal ofCancer (1997) 75(4), 589-592 C CancerResearch Campaign 1997